In:
Acta Dermato-Venereologica, MJS Publishing, Medical Journals Sweden AB, Vol. 104 ( 2024-06-19), p. adv38889-
Abstract:
A Swedish translation of the patient-reported outcome measure for assessing long-term control of atopic dermatitis, Recap of atopic eczema (RECAP), has not been validated. Cross-cultural translation and multi-centre validation of the translated RECAP questionnaire were therefore performed. Disease severity was assessed using the validated Investigator Global Assessment Scale for atopic dermatitis (vIGA-ADTM). The Swedish RECAP was completed by 208 individuals aged 16 years or older with a median age of 36 years (interquartile range [IQR] 27–48). The participants considered the questionnaire suitable for assessing eczema control. The median RECAP score (range 0–28) was 12 (IQR 5–19). The mean and median vIGA-ADTM scores (range 0–4) were 2 (standard deviation [SD] 2) and 3 (IQR 2–4), respectively. A correlation between RECAP and the vIGA-ADTM was observed (p 〈 0.001). There was no significant change in scores for participants who answered the questionnaire twice within 14 days. Over time, improved or worsened eczema, as evaluat-ed by vIGA-ADTM, affected RECAP scores significantly (p 〈 0.001). The study suggests that RECAP can assess AD control in a Swedish clinical setting and shows -acceptable reliability.
Type of Medium:
Online Resource
ISSN:
1651-2057
,
0001-5555
DOI:
10.2340/actadv.v104.38889
Language:
Unknown
Publisher:
MJS Publishing, Medical Journals Sweden AB
Publication Date:
2024
detail.hit.zdb_id:
1492617-9
Bookmarklink